Optibrium appoints Professor Andy Black as non-executive Chair Appointment brings extensive pharmaceutical services and Board experience to drive commercial growth and development of new products to improve speed, efficiency, and productivity of drug discovery ...
19 October 4.00pm (UK): Sensory properties are subjective measures assessed by panels of trained experts in an expensive and time-consuming process. We will be joined by our guest Dmitriy Chekmarev, to discuss the challenges of using this sparse and noisy sensory data...
3D Ligand-Based Drug Design: webinar In this webinar, we demonstrate intuitive workflows for 3D ligand-based drug design, allowing you to;• Enable 3D design, even with little or no target structure information• Find novel active compounds with 3D virtual screening...
Optibrium Releases 3D Ligand-based Design Modulefor StarDrop Drug Discovery Software Innovative predictive methods support virtual screening and compound design in the absence of 3D structure data. CAMBRIDGE, UK, 9 September 2021 – Optibrium Limited, a developer of...
Recent Comments